Catabasis Pharmaceuticals’ (CATB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) in a research report released on Tuesday morning. The firm currently has a $8.00 target price on the stock, down from their prior target price of $14.00.

Several other research firms also recently weighed in on CATB. Wedbush reiterated an outperform rating and set a $15.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, January 6th. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, March 2nd. Oppenheimer Holdings Inc. set a $11.00 target price on Catabasis Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 31st. Citigroup Inc downgraded Catabasis Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, February 1st. Finally, Cowen and Company downgraded Catabasis Pharmaceuticals from an outperform rating to a market perform rating and set a $4.00 target price on the stock. in a research report on Wednesday, February 1st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and an average target price of $5.70.

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals (NASDAQ:CATB) opened at 1.47 on Tuesday. Catabasis Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $7.89. The stock’s 50 day moving average price is $1.33 and its 200 day moving average price is $3.43. The company’s market capitalization is $27.78 million.

WARNING: This story was first published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.mideasttime.com/catabasis-pharmaceuticals-catb-buy-rating-reiterated-at-hc-wainwright/1589166.html.

Institutional investors have recently added to or reduced their stakes in the stock. Sphera Funds Management LTD. increased its position in Catabasis Pharmaceuticals by 90.9% in the third quarter. Sphera Funds Management LTD. now owns 387,943 shares of the company’s stock valued at $2,390,000 after buying an additional 184,700 shares during the period. Great Point Partners LLC bought a new position in Catabasis Pharmaceuticals during the third quarter valued at $1,540,000. Alyeska Investment Group L.P. increased its position in Catabasis Pharmaceuticals by 13.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 223,885 shares of the company’s stock valued at $808,000 after buying an additional 26,685 shares during the period. Federated Investors Inc. PA increased its position in Catabasis Pharmaceuticals by 45.1% in the fourth quarter. Federated Investors Inc. PA now owns 160,000 shares of the company’s stock valued at $578,000 after buying an additional 49,750 shares during the period. Finally, TLP Group LLC bought a new position in Catabasis Pharmaceuticals during the third quarter valued at $160,000. Institutional investors own 61.43% of the company’s stock.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.